Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Patrick J. Richardson"'
Autor:
Han-Mo Koo, George F. Vande Woude, Gabriela Bedolla, Alan T. Davis, Matthew W. Van Brocklin, Phyllis Stein, Kimberly J. Truszkowski, Michelle R. Bassett, Connie M. Szczepanek, Kathleen J. Yost, Timothy J. O'Rourke, Thomas J. Monroe, Alan D. Campbell, Charles R. Luttenton, Patrick J. Richardson, Craig P. Webb, Marianne K. Melnik
Supplementary Table 1 from Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20c864040888e732f9c20c2310c5c261
https://doi.org/10.1158/1535-7163.22485188
https://doi.org/10.1158/1535-7163.22485188
Autor:
Han-Mo Koo, George F. Vande Woude, Gabriela Bedolla, Alan T. Davis, Matthew W. Van Brocklin, Phyllis Stein, Kimberly J. Truszkowski, Michelle R. Bassett, Connie M. Szczepanek, Kathleen J. Yost, Timothy J. O'Rourke, Thomas J. Monroe, Alan D. Campbell, Charles R. Luttenton, Patrick J. Richardson, Craig P. Webb, Marianne K. Melnik
Prior studies suggest that tumor cell lines harboring RAS mutations display remarkable sensitivity to gemcitabine and etoposide. In a phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer, we evaluated the response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2ac05d7f09bbf7f596f622d484a34674
https://doi.org/10.1158/1535-7163.c.6531824.v1
https://doi.org/10.1158/1535-7163.c.6531824.v1
Autor:
Han-Mo Koo, George F. Vande Woude, Gabriela Bedolla, Alan T. Davis, Matthew W. Van Brocklin, Phyllis Stein, Kimberly J. Truszkowski, Michelle R. Bassett, Connie M. Szczepanek, Kathleen J. Yost, Timothy J. O'Rourke, Thomas J. Monroe, Alan D. Campbell, Charles R. Luttenton, Patrick J. Richardson, Craig P. Webb, Marianne K. Melnik
Supplementary Form 1 from Phase II Trial to Evaluate Gemcitabine and Etoposide for Locally Advanced or Metastatic Pancreatic Cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2caef588d4459fa29ca578f040067ac9
https://doi.org/10.1158/1535-7163.22485191.v1
https://doi.org/10.1158/1535-7163.22485191.v1
Autor:
Richard Axtell, Sanjeet Rangarajan, Dawna Dylewski, David Cherba, Deanna Mitchell, Sean Vance, Craig P. Webb, Stephanie B. Scott, Eric Lester, Emily Eugster, Paula J. Davidson, Noel R. Monks, Joseph J. Junewick, Nicole L. Beuschel, Patrick J. Richardson, David J. Monsma
Publikováno v:
Pediatric Blood & Cancer. 61:1570-1577
Background Precision (Personalized) medicine has the potential to revolutionize patient health care especially for many cancers where the fundamental disease etiology remains either elusive or has no available therapy. Here we outline a study in alve
Autor:
David J, Monsma, David M, Cherba, Patrick J, Richardson, Sean, Vance, Sanjeet, Rangarajan, Dawna, Dylewski, Emily, Eugster, Stephanie B, Scott, Nicole L, Beuschel, Paula J, Davidson, Richard, Axtell, Deanna, Mitchell, Eric P, Lester, Joseph J, Junewick, Craig P, Webb, Noel R, Monks
Publikováno v:
Pediatric bloodcancer. 61(9)
Precision (Personalized) medicine has the potential to revolutionize patient health care especially for many cancers where the fundamental disease etiology remains either elusive or has no available therapy. Here we outline a study in alveolar rhabdo
Autor:
Alan T. Davis, Phyllis Stein, Michelle R. Bassett, Timothy J. O'Rourke, Thomas Monroe, Matthew W. Van Brocklin, Kathleen J. Yost, Kimberly J. Truszkowski, Han Mo Koo, Alan D. Campbell, Charles R. Luttenton, Connie M. Szczepanek, Gabriela M Bedolla, Patrick J. Richardson, Marianne Melnik, Craig P. Webb, George F. Vande Woude
Publikováno v:
Molecular cancer therapeutics. 9(8)
Prior studies suggest that tumor cell lines harboring RAS mutations display remarkable sensitivity to gemcitabine and etoposide. In a phase II clinical trial of patients with locally advanced or metastatic pancreatic cancer, we evaluated the response
Autor:
Shravan Sridhar, Brad Bowles, Craig P. Webb, David Cherba, Aarati R. Ranade, Glen J. Weiss, Anoor Paripati, Patrick J. Richardson
Publikováno v:
Journal of Thoracic Oncology. (8):1273-1278
Purpose Although the majority of patients with small cell lung cancer (SCLC) respond to initial chemotherapy, those with disease progression at first response assessment (chemoresistance) have inferior outcomes. There is a need for predictive biomark